京东健康互联网医院
网站导航

山西省煤炭中心医院肝细胞性黄疸专家

简介:

山西省煤炭中心医院是国有非营利性医院,地处太原市学府街101号,占地面积150亩,固定资产5亿多元。医疗建筑面积达59900平方米,实际开放床位959张,为省城南部地区规模最大的集医疗、教学、科研、预防、康复为一体的省级综合性医院。山西省煤炭中心医院已被确定为山西省城镇职工基本医疗保险、山西省工伤医疗保险、太原市城镇职工基本医疗保险、太原市城镇居民医疗保险定点医院。山西省煤炭中心医院医疗设备总投资达两亿多元,配置有从美、日、德等国家引进的大型医疗检查与治疗设备近百台,最具代表性的、也是全省最先进的设备有派特CT、神经中央监护分析系统、罗氏生化分析组合系统、电子腹腔镜胆道镜以及数字化多功能X光胃肠机和全套电子胃镜、胶囊内镜、小肠镜等。山西省煤炭中心医院汇集了一批省内的权威专家来院担任相关学科带头人,形成强大的专家阵容。这些高等级的优秀技术专家德高望重,技术精湛。曾经都在山西医科大学第一医院、医科大第二医院、山西省人民医院、山西省肿瘤医院等担任过科室主任,是享有盛名的国家级专家和省级专家。有不少人享受国务院特殊津贴,学术地位在国内或山西省占有一席之地,其中也不乏国家级、省级劳动模范、全国三八红旗手、省十杰女职工等荣誉获奖者。设备先进,专家汇集,促进了山西省煤炭中心医院的快速发展,在按照三级综合医院的标准设置40多个临床专业科室的基础上,着力打造在全省极具影响力的神经病学、消化内镜、肿瘤放疗等三大中心,培育神经内科、肝胆胰外科、内窥镜检查与治疗、脑出血微创治疗、妇产科等五大特色专业,使山西患者不出省会就能够享受国家尖端水平的医疗服务。山西省煤炭中心医院已成为山西省医疗学术交流的重要基地之一,曾多次承担举办全国性和全省的学术专题会议,为医疗科学的发展做出了贡献。山西省煤炭中心医院为绿色医院建设的典范,就医环境优良,被太原市政府命名为环保模范医院。医院全部采用中央空调供暖供气。宽敞的门诊大厅设有自动扶梯和直梯,方便患者就诊和检查。各住院病区配置了中心供氧,每个病房配有卫生间、电视机、饮水机、衣柜等,有的病房还配备了冰箱、微波炉、沙发茶几,达到宾馆化配置。山西省煤炭中心医院实行人性化服务,建立患者绿色通道,为患者全程引导,感觉温馨如家。购置大型体检专用车辆深入村寨,走进田间地头为农民巡回医疗和体检。山西省煤炭中心医院以三级医院的高端配置、二级医院的低收费价格使广大患者得到更多的实惠,在2007年10月份荣立太原市劳动竞赛委员会“诚信经营”集体三等功等荣誉。肝细胞性黄疸是由于各种病因引起肝细胞发生了广泛性损害,致使肝细胞对非结合胆红素的摄取、结合发生障碍,故血清中非结合胆红素浓度增高,而部分未受损的肝细胞仍能继续摄取、结合非结合胆红素,使其转变为结合胆红素,但其中一部分结合胆红素未能排泌于毛细胆管中,而是经坏死的肝细胞间隙反流入肝淋巴液与血液中,或因肝细胞变性、肿胀、汇管区炎性病变以及毛细胆管、小胆管内胆汁淤积,胆栓形成,使结合胆红素的排泄受阻,结果造成结合胆红素经小胆管溢出反流入肝淋巴流与血液,最终导致血清中结合胆红素浓度也增高而出现黄疸。,本病是由于肝脏发育不成熟、缺氧、感染、先天性代谢性疾病、甲状腺功能低下、病毒性肝炎、肝硬化、肝癌等导致肝细胞广泛受损引起。,肝,1.保肝药物 如还原型谷胱甘肽、甘草酸苷制剂、门冬氨酸钾镁等。 2.中药 如茵栀黄注射液、苦参注射液或苦黄注射液等均有消炎、利胆及降黄作用,可酌情使用。,其他类型黄疸,禁忌喝酒、吃辛辣食物,血清总胆红素、非结合胆红素、结合胆红素、尿中胆红素、尿胆原、粪胆原、肝功能试验、肝脏组织学检查等。,。

曹彦明 副主任医师

甲癣(灰指甲),痤疮(青春痘),过敏性皮炎、湿疹,真菌性皮肤病(股癣,体癣,手足癣,甲),甲营养不良,病毒性皮肤病(寻常疣,扁平疣)牛皮癣(银屑病),带状疱疹,丹毒,尖锐湿疣等

好评 99%
接诊量 10w+
平均等待 30分钟
擅长:甲癣(灰指甲),痤疮(青春痘),过敏性皮炎、湿疹,真菌性皮肤病(股癣,体癣,手足癣,甲),甲营养不良,病毒性皮肤病(寻常疣,扁平疣)牛皮癣(银屑病),带状疱疹,丹毒,尖锐湿疣等
更多服务
宋日军 主任医师

对痤疮(闭合性粉刺,开放性粉刺等),各种癣,带状疱疹,荨麻疹,尖锐湿疣,淋病等性传播疾病有独到的见解。

好评 99%
接诊量 9.8万
平均等待 1小时
擅长:对痤疮(闭合性粉刺,开放性粉刺等),各种癣,带状疱疹,荨麻疹,尖锐湿疣,淋病等性传播疾病有独到的见解。
更多服务
杨星 副主任医师

不孕不育,复发性流产,常见的妇产科疾病

好评 99%
接诊量 1320
平均等待 -
擅长:不孕不育,复发性流产,常见的妇产科疾病
更多服务
郝志红 主任医师

呼吸内科常见病多发病的诊断及治疗。

好评 -
接诊量 -
平均等待 -
擅长:呼吸内科常见病多发病的诊断及治疗。
更多服务
李秀清 主任医师

备孕期优生优育指导,不孕不育原因查找;试管助孕心理咨询疏导;试管婴儿助孕指导,试管失败分析;卵巢功能减退和少弱畸形精子疾病治疗;对多囊卵巢,输卵管梗阻,子宫内膜息肉,妇科内分泌,胎停育保胎独特见解

好评 99%
接诊量 722
平均等待 -
擅长:备孕期优生优育指导,不孕不育原因查找;试管助孕心理咨询疏导;试管婴儿助孕指导,试管失败分析;卵巢功能减退和少弱畸形精子疾病治疗;对多囊卵巢,输卵管梗阻,子宫内膜息肉,妇科内分泌,胎停育保胎独特见解
更多服务
郝志峰 副主任医师

妇科各种阴道炎的诊治、外阴、阴道、宫颈HPV感染、癌前病变及早期癌的规范化诊断和保留子宫微创治疗,异常子宫出血性疾病的诊治及围绝经期健康指导、宫腔镜微创诊治不孕症、习惯性流产、宫腔粘连、内膜息肉、子宫纵隔、粘膜下肌瘤等宫腔病变。

好评 100%
接诊量 199
平均等待 15分钟
擅长:妇科各种阴道炎的诊治、外阴、阴道、宫颈HPV感染、癌前病变及早期癌的规范化诊断和保留子宫微创治疗,异常子宫出血性疾病的诊治及围绝经期健康指导、宫腔镜微创诊治不孕症、习惯性流产、宫腔粘连、内膜息肉、子宫纵隔、粘膜下肌瘤等宫腔病变。
更多服务
栾郁 副主任医师

常见内分泌科疾病的诊治,特别是糖尿病及甲状腺疾病,急慢性并发症的治疗

好评 -
接诊量 1
平均等待 -
擅长:常见内分泌科疾病的诊治,特别是糖尿病及甲状腺疾病,急慢性并发症的治疗
更多服务
任文霞 副主任医师

主要擅长妇科炎症,子宫肌瘤的诊治,产科常见合并症的诊治,及妇产科常见手术的操作。现主要治疗产科正常产及常见合并症的诊治,熟练掌握难产,剖宫产等的手术操作。

好评 -
接诊量 3
平均等待 -
擅长:主要擅长妇科炎症,子宫肌瘤的诊治,产科常见合并症的诊治,及妇产科常见手术的操作。现主要治疗产科正常产及常见合并症的诊治,熟练掌握难产,剖宫产等的手术操作。
更多服务
高小琴 副主任医师

辅助生殖试管婴儿,人工授精,不孕不育,不孕,保胎,取卵,移植,检测卵泡,促排,降调周期,染色体缺失,基因检测 ,遗传,子宫内膜,输卵管不通,促排卵,子宫内膜增厚,人工授精,女性备孕促排卵 ,促排卵助辅助生殖试管婴儿,人工授精促排卵 ,子宫内膜炎,促排卵助孕,子宫内膜薄,子宫内膜异位症,子宫内膜息肉,保胎助孕,子宫内膜癌,不孕症,子宫内膜异位,增厚子宫内膜,试管婴儿,备孕

好评 99%
接诊量 4197
平均等待 -
擅长:辅助生殖试管婴儿,人工授精,不孕不育,不孕,保胎,取卵,移植,检测卵泡,促排,降调周期,染色体缺失,基因检测 ,遗传,子宫内膜,输卵管不通,促排卵,子宫内膜增厚,人工授精,女性备孕促排卵 ,促排卵助辅助生殖试管婴儿,人工授精促排卵 ,子宫内膜炎,促排卵助孕,子宫内膜薄,子宫内膜异位症,子宫内膜息肉,保胎助孕,子宫内膜癌,不孕症,子宫内膜异位,增厚子宫内膜,试管婴儿,备孕
更多服务
李晓红 主任医师

子宫肌瘤 子宫腺肌症等消融处理

好评 -
接诊量 -
平均等待 -
擅长:子宫肌瘤 子宫腺肌症等消融处理
更多服务

患友问诊

宝宝14天大,黄疸数值299,照射三天后有所好转,询问治疗时间和方法。
10
2024-10-31 20:12:36
标本黄疸,无其他病史,需遵医嘱。
54
2024-10-31 20:12:36
我有肝炎的病史,最近脖子有点黄,可能是黄疸引起的。请问这种情况应该怎么办?
12
2024-10-31 20:12:36
宝宝出生后出现黄疸,数值在15到16之间,想了解是否需要照蓝光?
62
2024-10-31 20:12:36
一个月大的宝宝出现皮肤和眼睛发黄的症状,黄疸指数大约在10左右,想了解如何处理?
68
2024-10-31 20:12:36
我想了解新生儿黄疸的检测方法和治疗方式,是否有产品可以在家中检测黄疸?
42
2024-10-31 20:12:36
我想了解黄疸仪的使用方法和黄疸的标准值,网上看到的数值不太一样,希望能得到专业的解答。
20
2024-10-31 20:12:36
新生儿出生七天,面部有些发黄,想了解是否需要用产品治疗?
23
2024-10-31 20:12:36
用药后出现黄疸、头晕,怀疑药物副作用,同时有幽门螺旋杆菌感染。
41
2024-10-31 20:12:36
胆腹胀满,小便不利,黄疸症状,使用过苍附导痰丸,效果一般。
69
2024-10-31 20:12:36

科普文章

#肝细胞性黄疸
2

胆红素的排泄障碍里,它分三个阶段。第一个叫做胆红素生成过多,包括所说的有溶血的情况,也就是间接胆红素生成过多。第二种是胆红素的转化出现了功能障碍,最典型的就是肝细胞性黄疸,各种类型的肝炎。第三个是胆红素的排泄障碍,也就是胆红素生成是正常的,但是排出去的管路,比如说胆小管阻塞。所有针对黄疸的治疗药物有两个,一个是跟胆红素生成过程之中的,促进胆红素的生成和胆红素的肝肠循环,最常见的药物包括思美泰和熊去氧胆酸,这是非常有循证医学。第二类的药物,通过局部的离子浓度变化,促进胆汁排泄进入胆小管。最常见的药物是含有镁制剂的,门冬氨酸钾镁或者硫酸镁等一类的药物。

#肝细胞性黄疸#溶血性黄疸[阿杨-维达尔氏综合征]
12

根据黄疸病因的不同,不同类型的黄疸的治疗方案也不尽相同。因此,黄疸的病因诊断至关重要,我们需要根据黄疸患者情况针对性的进行治疗。对于急性期的黄疸,我们需要紧急处理,比如新生儿黄疸,梗阻性化脓性胆管炎,肝功能衰竭这些引起的黄疸都需要积极的治疗。

1.对于溶血性黄疸的治疗,由于主要是溶血性疾病引起的,包括先天性溶血性的疾病,如海洋性贫血等,还有后天获得性的溶血性疾病,如自身免疫性溶血、血型不合的输血等等,这种情况就需要医院血液科检查清楚,然后再做相关的治疗。

2.对于肝细胞性黄疸的治疗,是因为肝脏、肝细胞受到各种损害所引发的黄疸,比方病毒性肝炎、药物性肝损伤等等,则需要抗病毒保护肝细胞的治疗,同时配合使用一些:还原型谷胱甘肽,腺苷蛋氨酸,水飞蓟素,多烯磷脂酰胆碱,前列地尔等对症治疗。

3.对于胆汁淤积性黄疸的治疗,主要分为肝内胆汁淤积和肝外胆汁淤积。肝内胆汁淤积,如原发性胆汁性胆管炎,这是一种自身免疫性肝病,可以口服 熊去氧胆酸 进行治疗。肝外梗阻性胆汁淤积,如胆总管的结石、肿瘤等,则需要给予介入治疗来疏通胆管。

4.对于部分黄疸的患者,可以根据患者的实际情况决定是否需要进行手术治疗。具体包括胆道结石、肿瘤的控制,脾切除,肝移植等等。

 
#肝细胞性黄疸#黄疸病
46

患者朋友们大家好,我是温暖医生。很高兴和家人见面了。我们今天一起学习的科普知识是肝细胞性黄疸的病因与特点。临床上肝细胞性黄疸是比较常见的一种黄疸的类型,具体来说,主要是由于肝细胞的坏死而造成的进行性加重的黄疸。肝细胞性黄疸往往会合并肝功能功能的严重损伤,甚至出现肝功能衰竭的表现。

一般来说,肝细胞性黄疸的常见原因及特点主要有以下几点:

  • 药物性肝损伤。患者长期大剂量服用某种药物,造成了肝脏负担过重,引起肝细胞坏死的表现。肝细胞大量坏死后患者查血指标可表现为胆红素指标明显升高,而肝功能转氨酶的指标正常或轻度升高,这提示患者可能出现肝衰竭的症状。患者会有皮肤,巩膜的明显黄染,小便颜色呈浓茶样改变。
  • 肝硬化失代偿。无论各种原因造成的肝硬化失代偿,患者均会有不同程度的肝细胞损伤。这会引起患者黄疸指标进行性升高,出现肝细胞性黄疸的表现。肝硬化失代偿患者常常合并大量腹腔积液,依据门静脉高压等严重并发症。其预后往往较差。
  • 胆汁淤积性肝损伤,这常常是自身免疫性疾病造成的肝细胞损伤,也会出现进行性加重的黄疸,病情严重者后期常常发展为胆汁淤积性肝硬化。肝移植手术是目前唯一有希望彻底根治该疾病的方式之一。

以上就是今天的内容,欢迎大家留言交流。

#肝细胞性黄疸#溶血性黄疸[阿杨-维达尔氏综合征]#胆汁郁积症
19

黄疸是指血浆胆红素的浓度增高并且大于34.1微摩尔每升或者大于2毫克每分,并且沉积于组织中,然后引起巩膜,皮肤,粘膜以及其他组织和体液发生黄染的现象。

1.根据病因发病学分类:可以将黄疸分为以下4类:溶血性黄疸,肝细胞性黄疸,胆汁淤积性黄疸,先天性非溶血性黄疸。

2.根据胆红素的性质分类,可以分为以下两大类:(1)以结合胆红素升高为主的黄疸:这类型的黄疸以血清总胆红素升高为主,其中非结合胆红素占80%~85%以上。主要由肝前性因素引起,多见于胆红素生成过多,比如先天性或获得性溶血性黄疸,旁路性高胆红素血症等等,也可见于胆红素摄取障碍,比如说gilbert综合征,还可以见于胆红素结合障碍,比如说葡萄糖醛酸转移酶活力降低或者缺乏。(2)以结合胆红素增高为主的黄疸:此类型结合胆红素在总胆红素中所占比例一般大于30%,大多数都是由于胆红素在肝内转运排泄障碍或同时由胆红素摄取结合和排泄障碍引起。常见的病因主要有以下几大类:肝外胆管阻塞,比如说胆结石,胰头癌;肝内胆管阻塞,比如说广泛肝内胆管结石;或者是肝内胆汁淤积,比如肝炎药物性肝炎,妊娠期、多发性黄疸等等。

通过这类的分类方法,可以对胆红素代谢障碍的环节,还有可能导致胆红素代谢障碍的病因大概有个了解,从而进一步完善相关检查,明确诊断及制定有效的治疗方案。

#肝细胞性黄疸#溶血性黄疸[阿杨-维达尔氏综合征]#胆汁郁积症
25

黄疸是指血浆胆红素的浓度增高并且大于34.1微摩尔每升或者大于2毫克每分,并且沉积于组织中,然后引起巩膜,皮肤,粘膜以及其他组织和体液发生黄染的现象。

1.根据病因发病学分类:可以将黄疸分为以下4类:溶血性黄疸,肝细胞性黄疸,胆汁淤积性黄疸,先天性非溶血性黄疸。

2.根据胆红素的性质分类,可以分为以下两大类:(1)以结合胆红素升高为主的黄疸:这类型的黄疸以血清总胆红素升高为主,其中非结合胆红素占80%~85%以上。主要由肝前性因素引起,多见于胆红素生成过多,比如先天性或获得性溶血性黄疸,旁路性高胆红素血症等等,也可见于胆红素摄取障碍,比如说gilbert综合征,还可以见于胆红素结合障碍,比如说葡萄糖醛酸转移酶活力降低或者缺乏。(2)以结合胆红素增高为主的黄疸:此类型结合胆红素在总胆红素中所占比例一般大于30%,大多数都是由于胆红素在肝内转运排泄障碍或同时由胆红素摄取结合和排泄障碍引起。常见的病因主要有以下几大类:肝外胆管阻塞,比如说胆结石,胰头癌;肝内胆管阻塞,比如说广泛肝内胆管结石;或者是肝内胆汁淤积,比如肝炎药物性肝炎,妊娠期、多发性黄疸等等。

通过这类的分类方法,可以对胆红素代谢障碍的环节,还有可能导致胆红素代谢障碍的病因大概有个了解,从而进一步完善相关检查,明确诊断及制定有效的治疗方案。

病症: 胃癌 恶性黑色素瘤

患者:李女士

年龄:70岁

罹患癌症,毫无疑问对每个人都是重大打击。而如果一位患者不幸同时罹患两种癌症,我们可以想象得出他的心情会是怎样的沉重。

但时至今日,癌症早已不再是什么“不治之症”,很多良好的治疗方法,可帮助患者迈过重重困境,预后得到极大提升。

不仅如此,在医疗全球化的今天,中国患者也能通过“海外二诊”服务,快速触达到国际权威专家资源,为自己的治疗保驾护航!

今天的案例主人公李女士,正是一位“海外二诊”的受益者。我们来一起看看她的故事。*为保护隐私,文中患者个人信息均已经脱敏处理。

70岁的李女士在去年年底,因脚底疼痛去医院看病,结果发现脚后跟有一个1厘米的黑色肿物。医生判断是冻疮,于是开了点外用药,李女士也就没有再放在心上。

大概4个月后,真正的噩梦降临:李女士通过影像检查,被诊断为胃癌,而且有了淋巴结转移。 她还出现了多次呕血,病情非常危急。很快,医生为她实施了全胃切除。令人意想不到的是,几天后通过检查,医生发现李女士后脚跟的肿物竟然也是癌症——恶性黑色素瘤。于是大概2个月后,医生又切除了她的足底肿瘤。 

为了降低复发风险,李女士开始了3个周期的化疗联合免疫治疗(替吉奥联合纳武单抗)。

虽然该做的都已做完,但对于李女士来说,恐惧感还远未被消除。因为癌症最令人恐惧的,是其具有“复发转移”的能力 。一旦癌症再次袭来,李女士不知道自己该如何应对。另外,两种癌症的治疗以及术后辅助药物治疗,也让李女士遭遇了一些副作用。比如腹泻、味觉障碍还有体重明显下降的问题。这些对于已经70岁的李女士来说,都很影响生活质量,所以迫切需要解决。

在本次的国际专家“海外二诊”服务中,李女士预约的是来自日本某知名综合性医院肿瘤中心的外科部长医生,他的专长领域既包括肿瘤外科,又包括各类癌症药物疗法、姑息治疗,是一位“内外兼修”的权威专家。在充分了解了李女士既往的病情和治疗经过后,医生很快通过远程会诊的方式,为患者详细解答了当前她的所有问题。

1、 未来如果转移或复发了该怎么办?  

医生:假如您未来不幸出现转移或复发,那么化疗是核心治疗手段。对于单发的孤立转移灶,可以选择手术、放疗来进行局部治疗。

具体化疗方案选择,我按使用的先后顺序列出了3类,当前面的方案失效后,可更换为后面的方案。

一类方案:化疗联合/不联合免疫方案  

  • CAPOX (卡培他滨+奥沙利铂)±O药(即免疫药物纳武单抗)
  • SOX (替吉奥+奥沙利铂)±O药
  • FOLFOX (5-FU+奥沙利铂)±O药

二类方案:化疗联合/不联合抗血管药物方案  

  • Taxane (紫杉醇/白蛋白结合型紫杉醇/多西紫杉醇)±雷莫芦单抗

三类方案:化疗方案  

  • 曲氟尿苷/盐酸替吡嘧啶
  • 伊立替康

  2、N K细胞疗法是否对我有帮助?副作用是否可控?   X医生:目前尚没有证据表明NK细胞疗法对癌症有效,因此不予推荐。

3、口服替吉奥会腹泻,是否需要调整方案?   II/III期胃癌患者术后采用辅助治疗方案,分别为:

  • 替吉奥口服 1 年(口服 4 周,停药 2 周,共 8 个疗程或口服 2 周,停药 1 周,共 16个疗程)
  • CAPOX (卡培他滨+奥沙利铂) 共半年(每 3 周一次,共 8 个疗程)
  • SOX (替吉奥+奥沙利铂) 共半年(每 3 周一次,共 8 个疗程)

这三种方案中,替吉奥方案和CAPOX方案等效,但SOX要优于替吉奥。另外,胃癌术后直接使用纳武单抗免疫治疗无意义。

替吉奥确实会出现腹泻等代表性不良反应,患者可以考虑对症治疗,比如调节肠道的药物、止泻药等缓解副作用。如果副作用太严重,那么可以考虑减少药物剂量。

替吉奥的标准用药剂量为120mg,但用量低于80mg无法达到预期效果。如果当前患者用药为100mg,那么为了降低副作用,可以减少剂量到80mg;但如果目前剂量已经是80mg,则无法进一步降低剂量,此时考虑更换方案为CAPOX方案替代。 如果不良反应严重到干扰日常生活,则患者可以选择停药,持续观察病情变化。

对于无淋巴结转移的II期B和II其C的患者,可选择使用1年帕博丽珠单抗免疫治疗。

4 、术后患者很瘦,味觉障碍,如何调理改善?   通常,手术后患者体重会减轻20%左右。这是患者消化吸收能力低下、促食欲的胃肠激素减少引起的。大约6个月到1年时间,患者可以恢复正常。

味觉障碍可能是抗癌药的副作用引起的,也可能是饮食减少导致缺乏锌等微量元素引起的。建议患者采用少食多餐的方式饮食,每天分5-6次吃饭。在日本,我们有时也会给患者用一些营养补充剂。

另外,也可以考虑采用中草药的对症治疗,改善症状,比如十全大补汤、六君子汤。 会诊结束后,李女士的心情得到了极大的平复。她对自己未来要走的路更清晰了,也对日本专家的细致指导和会诊的快速响应非常满意。

中国是消化道癌症发病数量较多的国家,根据国家癌症中心发布的《2022年中国恶性肿瘤疾病负担情况》数据,2022年我国胃癌新发病例约为35.87万例,死亡人数26.04万人。

总体来说,胃癌属于严重威胁我国国民生命健康的蕞常见癌症之一。胃癌如能在早、中期发现,还是有很大机会通过手术实现根治的,患者仍有一定机会得到临床治愈(术后5年不复发即为临床治愈)。

但在胃癌患者中,一部分人会因为【年龄较高】、伴有诸多【基础病】等问题,对手术存有疑虑,担心“下不来手术台”,甚至会放弃手术机会,选择吃药等姑息治疗。这样的选择真的正确吗?现如今的技术能否支持这类老年患者安全手术呢?接下来,我们一起看一个真实案例。

01七旬老人遭遇中期胃癌

一位七十多岁的“老胃病”项女士,因短时间体重骤降(8斤)前往就医。血液检测显示,她有一项指标异常升高。进一步检查发现,她的食道和胃连接的地方(贲门)以及胃的“外墙”(胃壁)都变得异常的厚,而且形状不均匀——这正是胃癌常见的表现。

医生随后通过胃镜检查和病例活检(取一小块组织观察上面的细胞),确诊了老人患有胃癌。由于还没有出现胃以外的远处其他器官的转移,也没有附近淋巴结转移,因此项女士的胃癌分期为中期。虽不是早期,但中期胃癌通常是可以手术的。为项女士提供诊疗的医生也表示,可以通过全胃切除手术实现根治。

但一来项女士已经七十多岁,二来她有20多年的糖尿病(手术伤口会更慢愈合、感染风险高、术后并发症风险高)、右肺还有一枚1.2厘米的肺结节。种种问题让老人和家人们都比较犹豫,担心扛不住治疗,最终“越治越糟”。在这样的背景下,项女士决定找一位足够权威的外科专家,来为自己进行全面评估,看看能不能兼顾好肿瘤根治以及手术的安全性。

不久后,项女士预约了来自日本癌研有明医院消化中心胃外科部长布部创也医生为自己提供指导。

02日本专家咨询内容分享

在充分了解了项女士的病情信息和全部资料后,布部创也医生给出了如下指导建议:首先,患者此前接受的是普通CT而非增强CT,胃镜也没有清晰展示食道上肿瘤具体侵犯的程度,因此很难得出精准的分期判断。

后面患者来癌研有明医院就医时,医疗团队会在治疗前为她做一套非常精细、全面的检查,此后就可以明确肿瘤情况了。届时如果发现患者的分期、肿瘤侵犯的范围确实和现在的结果相同,那么可以通过一个腹腔镜微创手术实现根治,损伤会非常小;如果届时发现肿瘤侵犯食道过多,则需要消化道联合食道外科共同进行胸腔镜手术治疗。

但无论是哪一种情况,患者都可以耐受手术,并且保留一部分胃。癌研有明医院是一家极为擅长肿瘤微创手术的知名癌症专科医院。在胃癌方面,2005年,医院开始导入腹腔镜,2019年又引入了达芬奇手术机器人,患者术后并发症更少了。如今,癌研有明医院98%的外科手术都采用微创。

受益于此,很多在别的医院需要胃全切的胃癌患者,到癌研有明后可以保留一部分胃,还能兼顾临床治愈。这对于术后患者的长期营养摄入和体重维持都很有帮助。布部创也医生所在科室的主要目标之一,正是在做到根治性切除的前提之下,将原本的胃全切术式变为次全胃切除术,尽可能为患者保留一些胃,让他们未来的生活质量得到提升。

那么项女士的糖尿病问题,会不会影响到手术呢?对此,布部创也医生认为完全不必担心,因为对于这类患者,癌研有明医院会进行详细的术前评估,并且有专业团队介入,从生活方式调整和专业治疗入手,帮助患者控制好血糖,让血糖水平达到符合手术的标准,从而降低术后愈合不良风险。

关于肺部的1.2厘米结节,布部医生认为可以暂不处理,无论它到底是良性还是恶性。因为这枚结节属于纯磨玻璃结节,即便是恶性,进展也非常缓慢,并不会快速出现转移扩散。而胃癌根治手术虽然会采用微创方式,但依然会给患者带来一定的负担,如果同时处理肺结节,会导致负担过重、患者难以承受。所以当前蕞好的处理办法,是先集中精力解决胃癌肿瘤,术后安排呼吸科专家为患者进行肺结节诊断,给出随访或手术或根治性放疗的建议。

03项女士术后,是否需要化疗来降低复发风险、争取更大治愈希望?

对此,布部创也医生表示,是否化疗现在还不能判断。因为术后患者能获得蕞精准的分期判断,有可能患者术前被认为是2期,但实际上术后成了1期(无需化疗);有时也可能患者术前是1期,但术后成了2-3期。假如是2-3期,则患者术后需要坚持1年的辅助化疗,大概可以降低10%的复发风险。

当地时间10月29日礼来宣布了Ⅲb期临床试验(TRAILBLAZER-ALZ 6)的积极结果,对于早期症状性阿尔茨海默病成人患者,用改良滴定方案接受donanemab治疗的患者在24周主要终点时,伴水肿/积液的淀粉样蛋白相关影像学异常(ARIA-E)有所减少。

donanemab这个新药在今年7月获批于美国,又在之后获日本厚生劳动省、英国药品和医疗产品监管局批准,用于轻度阿尔茨海默病、轻度认知功能障碍的治疗。donanemab在国内2023年取得突破性治疗药物认定,并纳入优先审评审批程序,目前还在审评审批过程中。

CDE官网截图

但在FDA说明书中有黑框警告,大意是应用该药时应注意淀粉样蛋白相关影像学异常(ARIA),表现为ARIA-E和ARIA伴含铁血黄素沉积(ARIA-H),通常发生在治疗早期,且无症状,很少发生严重和危及生命的事件。本次试验的积极结果和这个黑框警告相关。一起来看详情。

FDA说明书截图

给药方式有哪些改变?会不会影响效果?

TRAILBLAZER-ALZ 6是一项多中心随机双盲Ⅲb期研究,主要研究donanemab的不同给药方案对早期症状性AD患者ARIA-E和淀粉样蛋白清除率的影响,这里的早期AD指的是轻度认知障碍(MCI)和轻度痴呆疾病阶段。

给药方式和既往不同,既往标准给药方案是在前三次输注时接受2瓶(700mg)donanemab,然后再接受4瓶(1400mg);改良滴定方式是患者第一次输注1瓶(350mg),第二次输注2瓶(700mg),第三次输注3瓶(1050mg),此后每次输注4瓶(1400mg)。

研究的主要终点是第24周时患者出现ARIA-E占总参与者的比例,结果显示接受改良滴定方式的患者ARIA-E发生率为14%,而标准给药方案为24%,相对风险降低41%。载脂蛋白E(APOE)是已知的阿尔茨海默病遗传风险因素的携带者,在这些患者中,19%患者在改良滴定时患有ARIA-E,而标准给药方案中为57%,相对风险降低67%。

看到这里你或许也有疑问,虽然ARIA-E的发生风险降低了,但改良滴定方案会不会影响疗效?答案是不会。

与接受标准给药方案的患者相比,改良滴定患者淀粉样斑块和p-tau217减少。改良滴定的患者的淀粉样斑块水平较基线平均降低 67%,而标准给药组患者为69%。

参考来源

1.Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase Ⅲb study.

2.CED官网.

3.A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6).

当地时间10月29日,阿西米尼(asciminib)获美国食品药品管理局(FDA)加速批准[1] ,用于慢性期新诊断的费城染色体阳性慢性粒细胞白血病(Ph+CML)成年患者。CML是一种骨髓和血细胞癌症,通常由费城染色体的异常染色体引起。在一线治疗中,约1/3的患者会出现下列问题:由于不良反应或者治疗无效而停止酪氨酸激酶抑制剂(TKI)治疗。

为了解决这一问题,需要开发新的药物,asciminib就是解决这一困境的新药。早在2022年8月,加拿大药物和卫生技术局(CADTH)建议[2] :“若满足条件,可通过公共药物计划报销asciminib用于治疗费城染色体阳性慢性粒细胞白血病。”

asciminib为何得到FDA的青睐?

本次获批基于一项III期多中心随机研究,研究目的是比较每日80mg的asciminib与TKI治疗的疗效。TKI治疗是接受伊马替尼、尼洛替尼、达沙替尼或博舒替尼任意一种治疗。

共有405名患者被随机分配(1:1)进两组治疗。主要疗效结局指标是48周时的主要分子反应(MMR)率。这个指标是慢性髓性白血病的关键指标,这个比例越高,说明该治疗在基因水平上对疾病的控制效果越好,能够更有效地抑制疾病相关基因的表达,进而有望更好地控制疾病的进展、改善患者的症状和预后。

研究结果显示,48周时MMR率方面,asciminib组中为68%(95% CI: 61, 74),TKI组为49%(95% CI: 42, 56),二者相差19%。细看具体的TKI,入组伊马替尼和其他TKI药物入组比例为1:1;asciminib组的MMR率为69%(95% CI: 59, 78),而伊马替尼组为40%(95% CI: 31, 50),相差近30%(95% CI: 17, 42)。

这个新药安全吗?每周需要打几次药?

根据FDA数据显示,在新诊断和既往接受过治疗的患者,应用新药最常见的不良反应(≥20%)是肌肉骨骼疼痛、皮疹、疲劳、上呼吸道感染、头痛、腹痛和腹泻。若只看新诊断的患者,最常见的实验室异常(≥40%)是淋巴细胞计数降低、白细胞计数降低、血小板计数降低、中性粒细胞计数降低等。

根据FDA已批准的asciminib说明书,用药期间还需要注意一下事项:

1.骨髓抑制 :用药期间可能因出现骨髓抑制,发生血小板减少症、中性粒细胞减少症和贫血。用药应在治疗的前3个月,需要每两周进行一次全血细胞计数,此后每月进行一次检测,从而判断患者有无骨髓抑制症状。根据严重程度,咨询医生是否需要停药。

2.胰腺毒性 :患者可能出现血清脂肪酶和淀粉酶无症状升高,每月需评估血清脂肪酶和淀粉酶水平,如果您有胰腺炎,则注意主动告知医生,需要进行频率更高的检测。

3.高血压风险 :可能出现3级或4级高血压风险,应注意检测血压。

4.超敏反应 :可能出现3级或4级超敏反应,包括皮疹、水肿和支气管痉挛。如果出现这些症状,需及时反馈医生,医生会根据超敏反应的体征和症状,开始适当的治疗。

5.心血管毒性 :如果您有心血管病史,需要告知医生;对于3级或更高级别的心血管毒性,医生会考虑暂停用药、减少剂量或永久停药。

6.胚胎/胎儿毒性 :若您在怀孕期间用药或在服用药物期间怀孕,可能对孩子有潜在风险。这个新药是口服药,需要根据不同的给药剂量(80mg或40mg)每天/或每两天用药。

近些年来,还有哪些白血病药物获批FDA?

根据FDA肿瘤学/血液系统恶性肿瘤批准通知,白血病相关新药整理如下表。

另外可以看出21年时asciminib已获批白血病治疗,但限定既往接受过两种或更多TKIs治疗,本次获批属于扩大适应证。

参考来源:

1.FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia. 2.Asciminib(Scemblix):CADTHReimbursementRecommendation:Indication:ForthetreatmentofadultpatientswithPhiladelphiachromosome-positivechronicmyeloidleukemia(Ph+CML)inchronicphase(CP)previouslytreatedwith2ormoretyrosinekinaseinhibitors.Ottawa(ON):CanadianAgencyforDrugsandTechnologiesinHealth;2022Aug.PMID:38713779. 3.AStudyofOralAsciminibVersusOtherTKIsinAdultPatientsWithNewlyDiagnosedPh+CML-CP. 4.Product information:SCEMBLIX-asciminibtablet,filmcoated.UpdatedAugust7,2024. 5.Oncology(Cancer)/HematologicMalignanciesApprovalNotifications.

以下内容来源于新英格兰医学杂志。

Presentation of Case

Dr. Carrie Chui (Neurology): A 79-year-old man was admitted to this hospital because of involuntary movements on the left side and transient unresponsiveness.
The patient had been in his usual state of health until 9 months before admission, when involuntary movements of the left shoulder and left side of the face developed. The movements were described by the patient as twitching, were not associated with a change in the level of consciousness, and resolved after 1 to 2 minutes. During the next 6 months, the patient had similar episodes approximately once per month, but the episodes increased in duration, lasting 5 to 6 minutes.
Three months before admission, the episodes of involuntary movements increased in frequency, and the patient was evaluated by his primary care physician. The physical examination was normal. Results of kidney-function tests were normal, as were blood levels of glucose and electrolytes, except for the sodium level, which was 129 mmol per liter (reference range, 135 to 145). There was a history of inappropriate antidiuretic hormone secretion, and the sodium level was similar to levels obtained during the past 4 years. Magnetic resonance imaging (MRI) of the head (Figure 1A), performed before and after the administration of intravenous contrast material, revealed a focus of enhancement in the right middle frontal gyrus that was thought to be a small vascular anomaly. Electroencephalography (EEG), performed with the patient in awake and drowsy states, revealed rare, brief, focal slowing in the left temporal lobe during drowsiness; no epileptiform abnormalities were present.
Figure 1
MRI of the Head and CT Angiogram of the Head and Neck.
Two months before admission, the patient was evaluated in the epilepsy clinic affiliated with this hospital. He reported that the episodes of involuntary movements had increased in both frequency and duration, occurring once or twice per day and lasting approximately 10 minutes. Episodes began with tingling and numbness in the left leg that prompted the patient to voluntarily stomp the left foot to relieve the uncomfortable sensation. Then, the patient had involuntary movements that he described as an uncontrollable invisible force moving the left leg and arm, with hyperextension of the arm backward and pronation of the wrist. There was associated numbness in the distal portions of the left third, fourth, and fifth fingers and involuntary movement of the left cheek. No prodromal symptoms occurred. The patient had awareness during the episodes, and after the episodes, he felt fatigued but had a normal level of consciousness, without confusion. The examination in the epilepsy clinic was normal. A diagnosis of seizure disorder was considered, and treatment with levetiracetam was started.
Three weeks before admission, the patient was again evaluated in the epilepsy clinic. He reported that the episodes of involuntary movements still occurred on a daily basis but had decreased in duration and involved only the left leg, without abnormal movements of the arm or face. Dizziness, headache, and weakness had developed and were attributed to the use of levetiracetam. The patient’s family had recorded a video of one of the episodes of involuntary movements. After reviewing the video, the patient’s neurologist thought that the episodes were less likely to be caused by seizures and more consistent with choreoathetoid movements. Cross-tapering of medications — with the simultaneous administration of levetiracetam in decreasing doses and clobazam in increasing doses — was initiated, and the patient was referred to the movement disorders clinic affiliated with this hospital.
On the morning of admission, an episode of involuntary movements of the left leg and left shoulder occurred and persisted for 1 hour. Several hours after the symptoms abated, the patient’s wife found the patient to be unresponsive; he was sitting in a chair. Emergency medical services were called, and when they arrived, the patient was responsive. The fingerstick blood glucose level was 180 mg per deciliter (10.0 mmol per liter) and the blood pressure 110/80 mm Hg. The patient was transported to the emergency department of this hospital for further evaluation.
In the emergency department, the patient reported dysuria and increased urinary frequency. The patient’s daughter noted that he had been more anxious during the past 3 years and occasionally had trouble with memory. Other medical history included Barrett’s esophagus, benign prostatic hypertrophy, chronic hepatitis B virus infection, eczema, gastroesophageal reflux disease, hypertension, nonischemic cardiomyopathy, and osteoporosis. There was no history of head trauma or extended loss of consciousness. Medications included aspirin, atorvastatin, doxazosin, finasteride, omeprazole, metoprolol, sacubitril, and valsartan. There were no known drug allergies. The patient was a lifelong nonsmoker and drank alcohol rarely; he did not use illicit drugs. His mother had had gastric cancer, and his sister had had esophageal cancer; there was no family history of seizures.
On examination, the temporal temperature was 36.8°C, the blood pressure 152/97 mm Hg, the pulse 65 beats per minute, the respiratory rate 16 breaths per minute, and the oxygen saturation 96% while the patient was breathing ambient air. The body-mass index (the weight in kilograms divided by the square of the height in meters) was 21.7. The blood pressure decreased to 130/63 mm Hg with standing. The patient was alert and interactive. The lower jaw was held to the left, but the nasolabial folds and smile were symmetric with activation. There were nonrhythmic, nonstereotyped, writhing movements of the left arm. Tone was normal, and strength was assessed as 5 out of 5 in the arms and legs. Results of liver-function and kidney-function tests were normal, as were blood levels of glucose and electrolytes, except for the sodium level, which was 125 mmol per liter. The lactate level was 2.1 mmol per liter (19 mg per deciliter; reference range, 0.5 to 2.0 mmol per liter [5 to 18 mg per deciliter]). The urinalysis was normal. Intravenous fluids were administered. Imaging studies were obtained.
Dr. Rajiv Gupta: Computed tomographic (CT) angiography of the head and neck (Figure 1B) revealed extensively calcified plaque with severe stenosis of the distal right common carotid artery (CCA), extending into the proximal right internal carotid artery (ICA), as well as stenosis of the right and left paraclinoid ICAs and the left vertebral artery at its origin. There was no vascular abnormality on the CT angiogram that corresponded to the abnormality in the right middle frontal gyrus seen on the previous MRI.
Dr. Chui: The patient was admitted to the hospital. On the second hospital day, the sodium level had increased to 130 mmol per liter, and the lactate level was normal. Additional imaging studies were obtained.
Dr. Gupta: MRI of the head showed no evidence of acute infarction. The focus of enhancement in the right frontal lobe that had been noted previously was not seen on the current MRI.
Dr. Chui: Blood levels of thyrotropin, cobalamin, and glycated hemoglobin and results of coagulation tests were normal. Screening tests for Lyme disease, tuberculosis, and syphilis were negative, as were tests for antibodies to cardiolipin and β2-glycoprotein. A test for antinuclear antibodies was positive, at a titer of 1:160 in a homogeneous pattern. During a physical therapy session, the patient had abnormal movements of the left leg, left arm, and left side of the face. The abnormal movements diminished when the patient used distraction techniques, such as thigh tapping, finger snapping, and walking while holding a glass of water.
The transient unresponsiveness that led to the patient’s admission was attributed to a combination of sedation from clobazam and hypovolemia. Treatment with clobazam was stopped, and hydration was encouraged. A diagnosis of functional neurologic disorder was considered; outpatient physical therapy with continued use of distraction techniques was recommended. The patient was discharged home on the third hospital day.
Episodes of involuntary movements continued to occur on a daily basis at home. Two weeks after discharge, when the patient was doing exercises while sitting in a chair and having a conversation with his wife, he suddenly stopped talking. She found him slumped in the chair with his eyes closed, no longer exercising. When she asked him questions, he repeatedly said “yes.” Emergency medical services were called, and when they arrived, the patient was alert, diaphoretic, and nonverbal. He had a facial droop on the left side and a right gaze preference. The fingerstick blood glucose level was 130 mg per deciliter (7.2 mmol per liter) and the blood pressure 120/60 mm Hg. The patient was transported to the emergency department of this hospital for further evaluation.
In the emergency department, the temporal temperature was 36.6°C, the blood pressure 143/63 mm Hg, the pulse 66 beats per minute, the respiratory rate 18 breaths per minute, and the oxygen saturation 98% while the patient was breathing ambient air. He was alert and interactive. There was a facial droop on the left side. There was no effort against gravity in the left arm. The patient was able to lift the left leg off the bed for 1 to 2 seconds. He had a right gaze deviation that could not be overcome and mild dysarthria. The remainder of the examination was normal. A diagnosis of stroke was considered, and emergency CT angiography was performed.
Dr. Gupta: CT angiography showed no evidence of acute territorial infarction and no changes in cerebrovascular disease.
Dr. Chui: On repeat physical examination performed after CT angiography, the gaze deviation and dysarthria had resolved, and strength was normal. Mild facial paralysis was present.
A diagnosis was made.

Differential Diagnosis

Dr. Albert Y. Hung: This 79-year-old man initially presented with involuntary movements of the left shoulder and face without associated loss of consciousness. Diagnosis of an unusual movement disorder, especially one that is present episodically, can be challenging. Videos brought in by the patient can be very useful. 1 Most movement disorders result from abnormal functioning of extrapyramidal circuits involving the basal ganglia, rather than a specific neuroanatomical lesion, and the first step toward diagnosis is to identify the type of abnormal movements. 2
Four salient aspects of this patient’s involuntary movements can help in characterizing the movement disorder before generating a differential diagnosis. First, the movements were paroxysmal, lasting for short periods of time with resolution between episodes. Second, the movements were nonstereotyped, appearing randomly and variably. Third, the movements were restricted to the left side of his body throughout the course, localizing the disease process to the right cerebral hemisphere. Finally, the symptoms were progressive, increasing in both duration and frequency.

Movement Disorders

This patient had abnormal involuntary movements, symptoms indicative of a hyperkinetic movement disorder. Tremor, the most common hyperkinetic disorder, is unlikely because the patient did not have rhythmic movements. Dystonia is also unlikely, because he did not have sustained muscle contractions that were causing twisting or abnormal postures of the legs, arms, head, neck, or face. Although the patient initially described the movements as twitching, his later descriptions are not suggestive of myoclonus or tics, which manifest as sudden, rapid, recurrent movements.
This patient’s neurologist described the involuntary movements as “choreoathetoid” after reviewing a video of an episode. Chorea, athetosis, and ballism make up a spectrum of involuntary movements that often occur in combination. Chorea refers to involuntary movements that are “dancelike” — irregular, random, unintended, and flowing from one body part to another. When these movements are slow and writhing (with a lower amplitude) and involve the distal limbs, the term athetosis is used. The presence of both chorea and athetosis in the same patient is referred to as choreoathetosis. When the movements are fast and flinging (with a higher amplitude) and involve the proximal limbs, the term ballism is used. Although the description of this patient’s movements was not clearly suggestive of ballism, hemichorea and hemiballismus often occur together.
The term dyskinesia can refer to any abnormal movements and is often used to describe hyperkinetic disorders that are induced by specific drugs, such as tardive dyskinesia induced by dopamine antagonists or dyskinesia induced by levodopa in patients with Parkinson’s disease. Often, dyskinesia manifests as chorea or choreoathetoid movements, but chorea and dyskinesia are not synonymous. This patient appears to have involuntary dyskinesia with choreoathetosis as the primary phenomenology. Before constructing a differential diagnosis for dyskinesia in this patient, I will consider two conditions that mimic dyskinesia: seizures and functional movement disorder.

Seizures

Various movement disorders may be mistaken for seizures, although these movement disorders are not associated with EEG abnormalities during the episode. Patients with some forms of epilepsy may present with abnormal movements without other features that are typically associated with seizures, such as aura, change in responsiveness, incontinence, or a postictal state. 3,4 Seizures were initially suspected in this patient, and he was referred to the epilepsy clinic. Recurrent focal seizures were probably suspected because of the transient nature of the episodes. Initial MRI had shown a small abnormality in the right middle frontal gyrus, but this finding was not seen on follow-up imaging, which makes it unlikely to be related to the overall presentation. Baseline EEG had shown only brief left temporal slowing, without epileptiform abnormalities. The EEG was an interictal study, so the findings do not rule out seizures. However, the slowing was ipsilateral to the abnormal movements, so it is unlikely to be related to the episodes. In addition, the patient’s involuntary movements were nonstereotyped and nonrhythmic, which makes his presentation unlikely to be due to a seizure disorder.

Functional Movement Disorder

Because this patient’s movements diminished with the use of distraction techniques, a diagnosis of functional movement disorder was considered. Most cases of functional movement disorder begin abruptly after a trigger, such as a mild physical injury or illness; a psychological stressor can be present but is not required for diagnosis. Symptoms are typically most severe around the time of onset and may wax and wane over time. Although distractibility is a finding associated with functional disorders, abnormal movements that occur with nonfunctional syndromes can sometimes be suppressed by action or incorporated into voluntary movements in a manner that may appear distractible. Several clinical features in this patient make a diagnosis of functional disorder unlikely. Functional movement disorder is more common in women than in men, and the average age at onset is 40 years. 5 In addition, tremor is the most common clinical phenotype seen in patients with functional movement disorder; chorea or choreoathetosis, which was seen in this patient, is very unusual in patients with functional movement disorder. Overall, functional movement disorder is unlikely to explain this patient’s presentation.

Dyskinesia

Primary paroxysmal dyskinesia refers to a group of heterogeneous syndromes characterized by recurrent involuntary movements that occur episodically and abruptly, without loss of consciousness. 6 These disorders usually begin in childhood or young adulthood. Both the age of this patient and the described phenomenology make a diagnosis of primary paroxysmal dyskinesia unlikely.
The differential diagnosis in this case is therefore focused on causes of secondary dyskinesia, of which there are many. 7 MRI ruled out the presence of a mass lesion suggestive of cancer. The patient had no history of acute illness suggestive of a viral or other infectious encephalitis, and there was no history of trauma or exposure to drugs or other toxins. Although his daughter mentioned trouble with memory, there was no compelling history suggestive of a neurodegenerative disease.
A common metabolic cause of secondary dyskinesia is diabetic striatopathy, a syndrome involving the acute-to-subacute onset of chorea and ballism in the context of hyperglycemia. 8 This syndrome can occur as the initial manifestation of type 2 diabetes mellitus or as a complication of poorly controlled diabetes. Diabetic striatopathy is more likely to develop in women than in men, and the average age at onset is 70 years. Most patients present with hemichorea and hemiballismus, rather than bilateral symptoms. CT shows hyperdensity, and T1-weighted MRI shows hyperintensity, in the contralateral basal ganglia. However, this patient had no history of diabetes and had a normal blood glycated hemoglobin level, features that rule out a diagnosis of diabetic striatopathy.
Choreiform movements can also be a manifestation of autoimmune conditions. 9 This patient’s initial presentation with unilateral shoulder and face movements would have suggested the possibility of faciobrachial dystonic seizures associated with anti–leucine-rich, glioma-inactivated 1 (anti-LGI1) encephalitis. 10 This condition is often associated with hyponatremia, which was present in this patient. However, as the case evolved, leg involvement and sensory changes developed that would be atypical for anti-LGI1 encephalitis.
One key clue in this case is that the patient did not have an isolated movement disorder. In addition to motor symptoms, he had a variety of sensory symptoms involving both the left arm and the left leg. His first hospital admission was precipitated by an episode of unresponsiveness. The clinical event that led to his second presentation to the emergency department was distinctly different: an acute onset of speech difficulty accompanied by left hemiparesis and right gaze deviation that was worrisome for an acute right middle cerebral artery (MCA) syndrome. The symptoms resolved without intervention, which indicates that he may have had an acute transient ischemic attack (TIA). The most relevant imaging finding was severe cerebrovascular disease, including severe stenosis of the distal right CCA and proximal right ICA. Could this patient’s movement disorder be explained by a vascular lesion?

Limb-Shaking TIAs

Limb-shaking TIAs were first described by C. Miller Fisher in 1962. 11 In most case reports, these episodes are associated with high-grade stenosis of the ICA, which was seen in this patient. 12,13 The mechanism is thought to be cerebral hypoperfusion, and changes in posture or head position that decrease cerebral blood flow can precipitate these episodes. In this patient, the first episode of unresponsiveness that led to hospital admission occurred when he was sitting. He then had an acute episode involving right gaze preference that was provoked by exercise and was very suggestive of a TIA in the right MCA territory. These findings are highly suggestive of a diagnosis of limb-shaking TIAs, and I would refer this patient for emergency carotid endarterectomy.

Clinical Impression and Initial Management

Dr. Scott B. Silverman: When I evaluated this patient, his transient right gaze preference and left hemiparesis were consistent with a right MCA syndrome due to a TIA from symptomatic severe stenosis of the right ICA. The mechanism of this event was either artery-to-artery embolism or hypoperfusion. His previous, recurrent episodes of transient choreoathetosis on the left side that had occurred mainly while he was sitting, standing, or exercising were consistent with limb-shaking TIAs from hypoperfusion or low flow.
The pathogenesis of a low-flow state related to severe carotid stenosis resulting in limb-shaking TIAs is described in a small case series. 14 In six out of eight patients, the transient, stereotyped, involuntary movements were eliminated with carotid artery revascularization. Positional cerebral ischemia in patients without orthostatic hypotension has been described. 15
Treatment with atorvastatin was continued, the dose of aspirin was increased to 325 mg per day, and an intravenous heparin infusion was started. The strategy of permissive hypertension was used, with high blood pressure allowed to a maximum systolic blood pressure of 180 mm Hg. The patient was admitted to the stroke service, and carotid artery duplex ultrasonography was performed.
Dr. Gupta: Doppler ultrasonography of the carotid arteries (Figure 2) revealed markedly elevated Doppler flow velocities within the proximal right ICA. There was a parvus et tardus waveform in the distal right ICA, a finding indicative of low flow related to the more proximal high-grade stenosis. The Doppler waveform contours had poststenotic turbulence.
Figure 2
Doppler Ultrasound Image.
Dr. Silverman: The vascular surgery service was consulted, and the patient underwent right carotid endarterectomy.

Clinical Diagnosis

Limb-shaking transient ischemic attacks.

Dr. Albert Y. Hung’s Diagnosis

Limb-shaking transient ischemic attacks due to severe carotid stenosis, with secondary paroxysmal dyskinesia.

Pathological Discussion

Dr. Caroline F. Hilburn: The endarterectomy specimen included the carotid bifurcation and was notable for firm arterial walls, a finding consistent with calcification. On gross examination (Figure 3A), a large plaque was centered at the carotid bifurcation and protruded into the lumen, resulting in a maximal luminal stenosis of 80%. The plaque had an irregular and focally friable surface. On microscopic examination (Figure 3B), the plaque was characterized by extensive calcification. Some regions of the plaque had a smooth, healed fibrous cap, whereas other regions had an irregular surface suggestive of ulceration, which indicated potential sites of plaque rupture. Multiple smaller calcified plaques were present, affecting both branches of the artery.
Figure 3
Endarterectomy Specimen.

Pathological Diagnosis

Complex atherosclerotic plaque with portions of attached media.

Additional Management

Dr. Silverman: After the procedure, the patient had an uneventful recovery and was discharged home on the fifth hospital day. He was seen 1 month after discharge in the stroke prevention clinic. There had been no further episodes of involuntary movements or choreoathetosis and no stroke or TIA. The patient continues to take aspirin, atorvastatin, and antihypertensive medications.

Final Diagnosis

Limb-shaking transient ischemic attacks.
药品使用说明
打开京东APP
实惠又轻松
打开京东APP
京ICP备11041704号
京公网安备 11000002000088号